International journal of surgery (London, England) · 2025
Retrospective cohort study of ocular adverse reactions to systemic drugs: insights from a multi-country spontaneous reporting database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Shi-Nan, Huang Caihong, Chen Xiao-Dong, Liu Qian-Ting, Chen Lin, Wang Shao-Pan, Hu Jiaoyue, Liu Zuguo
Аннотация
BACKGROUND: With the rise in long-term medication use, assessing ocular adverse reactions (OARs) from systemic drugs has gained importance. Using large real-world databases like the FDA Adverse Event Reporting System (FAERS) offers valuable clinical and pharmacovigilance insights.
METHODS: Disproportionality analysis, including the ratio of reported odds (ROR), was performed on all OAR reports related to systemic medications in the FAERS database from 2004 Q1 to 2024 Q3. The OARs were categorized into disease-based and symptom-based classifications to identify systemic medications with positive signals.
RESULTS: In the FAERS database, the most common OARs were cataract, dry eye, and glaucoma, with blurred vision, visual impairment, and eye pain as the leading symptoms. Through disproportionality analysis, 141 systemic medications with positive signal drugs for OAR risks were identified, which were concentrated in the following categories: antineoplastic medication [30 drugs, belantamab mafodotin ROR (95% confidence interval): 59.59 (56.25-63.13)], central nervous system medication [21 drugs, fingolimod, 2.69 (2.63-2.75)], anti-infective medication [15 drugs, moxifloxacin, 6.52 (6.21-6.84)], immunological and inflammation-related medication [15 drugs, dupilumab, 4.74 (4.7-4.79)], cardiovascular system medication [10 drugs, ivabradine, 3.06 (2.61-3.58)], endocrine and metabolic disease medication [10 drugs, insulin lispro, 3.63 (3.4-3.89)], respiratory system medication [6 drugs, telithromycin, 3.51 (3.14-3.93)], and other medication [34 drugs, botulinum toxin type A, 4.24 (4.12-4.36)].
CONCLUSION: This pharmacovigilance study underscores the importance of identifying under-recognized OARs from systemic drugs to prevent secondary eye diseases and improve drug safety.
METHODS: Disproportionality analysis, including the ratio of reported odds (ROR), was performed on all OAR reports related to systemic medications in the FAERS database from 2004 Q1 to 2024 Q3. The OARs were categorized into disease-based and symptom-based classifications to identify systemic medications with positive signals.
RESULTS: In the FAERS database, the most common OARs were cataract, dry eye, and glaucoma, with blurred vision, visual impairment, and eye pain as the leading symptoms. Through disproportionality analysis, 141 systemic medications with positive signal drugs for OAR risks were identified, which were concentrated in the following categories: antineoplastic medication [30 drugs, belantamab mafodotin ROR (95% confidence interval): 59.59 (56.25-63.13)], central nervous system medication [21 drugs, fingolimod, 2.69 (2.63-2.75)], anti-infective medication [15 drugs, moxifloxacin, 6.52 (6.21-6.84)], immunological and inflammation-related medication [15 drugs, dupilumab, 4.74 (4.7-4.79)], cardiovascular system medication [10 drugs, ivabradine, 3.06 (2.61-3.58)], endocrine and metabolic disease medication [10 drugs, insulin lispro, 3.63 (3.4-3.89)], respiratory system medication [6 drugs, telithromycin, 3.51 (3.14-3.93)], and other medication [34 drugs, botulinum toxin type A, 4.24 (4.12-4.36)].
CONCLUSION: This pharmacovigilance study underscores the importance of identifying under-recognized OARs from systemic drugs to prevent secondary eye diseases and improve drug safety.